V Square Quantitative Management LLC Sells 1,524 Shares of Pfizer Inc. $PFE

V Square Quantitative Management LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 60,716 shares of the biopharmaceutical company’s stock after selling 1,524 shares during the quarter. V Square Quantitative Management LLC’s holdings in Pfizer were worth $1,472,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. GAMMA Investing LLC raised its stake in Pfizer by 4,183.6% during the 1st quarter. GAMMA Investing LLC now owns 1,599,742 shares of the biopharmaceutical company’s stock valued at $40,537,000 after purchasing an additional 1,562,396 shares during the period. Cascade Investment Advisors Inc. raised its stake in Pfizer by 2.0% during the 1st quarter. Cascade Investment Advisors Inc. now owns 64,409 shares of the biopharmaceutical company’s stock valued at $1,632,000 after purchasing an additional 1,265 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its stake in Pfizer by 35.9% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 120,285 shares of the biopharmaceutical company’s stock valued at $3,048,000 after purchasing an additional 31,766 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.6%

PFE opened at $23.75 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a fifty day moving average price of $24.55 and a 200-day moving average price of $24.12. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market cap of $135.03 billion, a price-to-earnings ratio of 12.63, a PEG ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PFE. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Bank of America raised their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.